Sign up for Breaking News Email Alerts

Neuralstem News

Press Releases


Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

Coverage Highlights

8.1.14 Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research.
7.30.14 The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online.
November 2013 FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology.
11.20.13 FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured.
November-December 2013 Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189.
October 2013 Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.”
8.28.13 FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial.
5.30.13 Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.”
9.13.12 MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury.

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

News Coverage

 

  • NFL alumni take stance on front line of effort to treat brain injuries

By Craig Wolff, The Star-Ledger (NJ), April 25, 2013

Reporter Craig Wolff talks to former San Diego Charger Wayne Clark about Neuralstem’s and the National Football League Alumni Association’s new initiative to develop an NSI-189/traumatic brain injury trial for treating NFL alumni. “I’d be willing to participate in anything,” Clark said. “And I’d expect all of us, no matter our present condition, would do the same.”

View Article

  • NFL may test brain injury treatment on retired players

By CBS News reporters/AP, April 24, 2013

“When in doubt, sit it out.” CBS, reporting with AP, added to the Neuralstem-NFLAA NSI-189/TBI story citing the American Academy of Neurology researchers’ new guidelines that call for current athletes who have sustained a significant head injury during a game be removed from play.

View Article

  • NFL group, company teaming up for brain drug test

Reported by Associated Press, April 24, 2013

AP coverage of Neuralstem-National Football League Alumni Association initiative to develop a trial for treating NFL alumni members suffering from traumatic brain injuries with neurogenic NSI-189 was carried by numerous media outlets ranging from ABC News to The Washington Post.

View Article

  • NFL Alumni Back New Drug to Keep Brain-Injuries From “Destroying Quality of Life”

By Erik Derr, Latinos Post, April 24, 2013

The NSI-189/TBI initiative by Neuralstem and the National Football League Alumni Association, to develop a trial to treat traumatic brain injury for former NFL players, is spotlighted.

View Article

  • Drug which could reverse depression symptoms draws interest of NFL Alumni Association

By Craig Wolff, The Star-Ledger (NJ), April 24, 2013

Lee Nystrom, Chairman of the Board, Emeritus of the NFL Alumni Association, which is headquartered in Newark, New Jersey, and Neuralstem’s CEO and President Richard Garr are quoted in this article about the new NFLAA-Neuralstem NSI-189/TBI initiative.

View Article

More Articles...

  1. Neuralstem, NFL Alumni Association To Test Feasibility Of Traumatic Brain Injury Treatment
  2. Football and Concussions: New Drug To Be Tested on NFL Alumni
  3. Michigan University Joins Lou Gehrig’s Clinical Trial
  4. Neuralstem Expands Lou Gehrig’s Disease Trials
  5. U-M May Recruit ALS Patients for Stem Cell Clinical Trial

Privacy and Terms ©Neuralstem, Inc. 2016